Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$153.90 USD

153.90
1,739,975

+4.14 (2.76%)

Updated Nov 4, 2024 01:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues

AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.

    Tirthankar Chakraborty headshot

    Tariff Woes Haunt Wall Street: Take Refuge in These 5 Stocks

    Companies involved in artificial intelligence, e-commerce, biotechnology and gaming businesses are immune to trade conflicts. They are part of an evolving trend that provides stability during tough times and their quest for the next big thing fuels growth.

      Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day

      Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day

        Madeleine Johnson headshot

        Bull of the Day: Illumina (ILMN)

        Invest in the medical space with this DNA sequencing-focused company.

          Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates

          Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.

            Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates

            Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.

              Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

              Is (ILMN) Outperforming Other Medical Stocks This Year?

                Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance

                Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.

                  athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View

                  An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.

                    Sprint (S) Gears Up for Q1 Earnings: What's in the Cards?

                    Sprint (S) is likely to report lower revenues in first-quarter fiscal 2018 on a year-over-year basis due to weak demand patterns in the industry.

                      What's in the Cards for Arena (ARNA) This Earnings Season?

                      With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.

                        Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

                        Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.

                          Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View

                          Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.

                            Why Earnings Season Could Be Great for Illumina (ILMN)

                            Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                              Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                              Sector ETF report for ARKG

                                McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View

                                Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.

                                  Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates

                                  Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.

                                    The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group

                                    The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group

                                      Integra (IART) Reports In-Line Q2 Earnings, Tapers View

                                      Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.

                                        Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates

                                        Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.

                                          AbbVie Secures FDA Approval for Endometriosis Drug Elagolix

                                          AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.

                                            Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View

                                            Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.

                                              What's in the Cards for CVS Health (CVS) in Q2 Earnings?

                                              CVS Health (CVS) is optimistic about living up to its strong earnings surprise history year over year in Q2 as well, courtesy of gains from the Pharmacy Services segment.

                                                LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View

                                                LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.

                                                  Swarup Gupta headshot

                                                  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions

                                                  Biotech stocks are largely resilient to trade related disruptions.